Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Participants With PPF

NCT06329401 is registered in ClinicalTrials.gov with Avalyn Pharma Inc. as lead sponsor.

NCT NCT06329401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06329401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Participants With PPF
Lead sponsor
Avalyn Pharma Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 3, 2024
Completion date
June 30, 2027
Enrollment
375 (estimated)
Sites
154

Conditions

As the registry lists them; a condition with its own page is linked.

hypersensitivity pneumonitis, interstitial lung disease, interstitial lung disease due to connective tissue disease (disorder), interstitial lung disease in patients with rheumatoid arthritis, interstitial lung disease with progressive fibrotic phenotype in diseases classified elsewhere, interstitial lung disease with systemic sclerosis, progressive pulmonary fibrosis, pulmonary fibrosis, pulmonary fibrosis secondary to systemic sclerosis, pulmonary fibrosis, interstitial lung disease